Novavax Inc (NASDAQ:NVAX) announced that peer-reviewed results from a Phase 3 efficacy trial of the R21/Matrix-M malaria vaccine were published in The Lancet on Friday.
The trial was conducted across multiple sites in four African countries with 4,800 children aged 5-36 months.
Data from this trial served as the basis for the World Health Organization’s (WHO) recent prequalification of the R21/Matrix-M vaccine, paving the way for a global rollout expected to commence in mid-2024 by Serum Institute of India.
The publication reported:
- In areas with highly seasonal malaria transmission (where malaria transmission is largely limited to four or five months ...